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Abstract 
The fibronectin monomer is comprised of three types of homologous repeating units, the types I, II, and 111 elements. Each type 111 
repeat is encoded by two exons except for the two type 11I repeats involved in alternative splicing (IIIB and IIIA) and the type 111-9 repeat 
which are all encoded by one exon. The fact that the type 111-9 repeat is the only other type III repeat encoded by one exon has led to 
speculation that this exon may also be alternatively spliced. However, no evidence xists for alternative splicing of this exon in any 
tissues examined to date. The recent localization of a cell adhesion synergy site within the type 111-9 repeat increases the likelihood of 
functional ramifications if the exon encoding this repeat is alternatively spliced in specific ells or tissues. We have shown previously that 
chick cartilage contains an unusual fibronectin mRNA splicing pattern and that the pattern changes during chondrogenesis from 
B + A + V + to B + A - V +.  In order to completely characterize the fibronectin mRNA in cartilage and other mesenchymal tissues for 
all possible alternative splicing events, we have determined whether or not the exon encoding the type 111-9 repeat is alternatively spliced 
in these tissues. RNase protection and RT/PCR assays indicate that the fibronectin mRNA in all of these tissues, including cartilage, 
contains the type 111-9 repeat as a constitutively included exon. Thus the exon encoding the type Ill-9 repeat will serve as a useful control 
exon for examining the regulation of tissue-specific alternative splicing during chondrogenesis. 
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1. Introduction 
Fibronectin, a dimeric glycoprotein present in plasma 
and the extracellular matrix of many tissues, participates in
several critical cellular processes including differentiation, 
adhesion, migration, and maintenance of cell morphology. 
Individual fibronectin monomers are comprised of three 
types of homologous repeating units, the types I, II, and III 
elements. These repeating elements form a series of func- 
tional domains that have specific binding affinities for a 
variety of biological structures uch as the cell surface, 
collagen, fibrin, and heparin (for review, see Ref. [1]). 
Even though the general structure of each fibronectin 
monomer is highly conserved, heterogeneity exists in its 
primary amino acid structure. This heterogeneity is largely 
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due to the alternative splicing of at least three exons 2 
(IIIB, IIIA, and V) during the post-transcriptional process- 
ing of the primary transcript from a single fibronectin gene 
[1]. Two of the known alternatively spliced exons (IIIB 
and IIIA) each encode one entire type III repeat and can 
either be included or excluded from the mature fibronectin 
mRNA using a form of alternative splicing known as exon 
skipping [2-5]. The third known alternatively spliced exon 
(V, for variable region) has no homology with the types I, 
II, or III repeating elements, but is located between the 
type III elements nearest the carboxy-terminus of the 
molecule. Thus this exon is often referred to as III-CS 
(type III connecting segment) [1]. Multiple splice varia- 
tions involving complex exon subdivision exist for exon V 
with the number of possible variations depending on the 
species [2,6,7]. 
2 Hereafter we will use the term 'exon' to refer not only to a coding 
segment of the fibronectin gene, but also to the comparable s gment of 
the mRNA. The term 'type HI repeat' will refer to a domain within the 
fibronectin protein. 
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Table 1 
Oligonucleotide primers 
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Primer name Exon location Sequence 
5' Primers 
VB108 III-7B 
VB112 III-8A 
VB161 IlI-8A 
3' Primers 
VB 111 Ili- 10A 
VB 113 11I-9 
TCAGAATTCGAGCATCCCCATCTCCAAAACCATC 
TCAGAATTCGAAGGAGGAGGACGTTGCAGAGC 
TCAGAATTCCCGCTFCACTAATGTGGGGCCTG 
AGTGGATCCGGGGTTGACTTCCAGGTCCCTTGG 
AGTGGATCCGTrGGTGAGAGTGATGGAGTTTCG 
The sequence and exon location of specific oligonucleotide primers utilized in RT/PCR reactions are indicated. All primer sequences are oriented 5'to 3'. 
Restriction enzyme sites in each primer are underlined. 
The splicing patterns for these three exons appear to be 
regulated independently of each other, and are regulated in 
a cell, tissue or developmental manner. For example, we 
have shown that chick cartilage contains an unusual form 
of fibronectin mRNA and that its splicing pattern changes 
during chondrogenesis [8], the differentiation of mes- 
enchyme into cartilage. All of the fibronectin mRNA from 
cartilage contains exon IIIB and exon V but does not 
contain exon IIIA (B + A-  V + ), whereas all of the 
fibronectin mRNA in limb mesenchyme prior to overt 
chondrogenesis or myogenesis contains exon IliA, exon 
IIIB, and exon V (B + A + V + ). Thus the splicing pat- 
tern of the fibronectin mRNA changes from B + A + V + 
to B + A - V + during chondrogenesis [8]. 
Each type III repeat in the fibronectin molecule is 
encoded by two exons except for the two type Ill repeats 
involved in exon skipping (IIIB and IliA) and one other 
type III repeat (111-9) which are all encoded by a single 
exon [4,9]. The fact that the type 111-9 repeat is the only 
other type III repeat known to be encoded by one exon has 
led to some speculation that this exon may be alternatively 
spliced as well [4,9]. However, no evidence presently 
exists for alternative splicing of the exon encoding the type 
111-9 repeat. The fibronectin mRNA from all cell types 
examined previously contains the exon encoding the type 
111-9 repeat: rat fibroblasts, adipocytes, and hepatocytes 
[4]; normal and transformed human cell lines, human adult 
liver and placenta, and human fetal liver, lung, kidney, and 
brain [9] and day 7 whole chick embryos (P. Norton, 
personal communication). In order to completely charac- 
terize the fibronectin mRNA in cartilage and other mes- 
enchymal tissues for all possible alternative splicing events, 
we have utilized RNase protection assays and reverse 
transcription followed by the polymerase chain reaction 
(RT/PCR 3) to determine whether or not the exon encod- 
ing the type 111-9 repeat is alternatively spliced in these 
tissues. These experiments indicate that the fibronectin 
mRNA in all tissues, including cartilage, contains the exon 
3 The abbreviations u ed are: PCR, polymerase chain reaction; 
RT/PCR, reverse transcription/polymerase chainreaction. 
encoding the type 111-9 repeat. Thus this exon does not 
appear to be alternatively spliced in any of the mesenchy- 
mal tissues we examined. In order to complete this work, 
we have determined previously unknown cDNA sequence 
for the 3' end of exon IIIB and the exons encoding the type 
Ill-8 repeat in the chick fibronectin gene. 
2. Materials and methods 
2.1. Tissues, cell culture, and RNA isolation 
The following tissues were isolated from white leghorn 
chick embryos (Truslow Farms, Chestertown, MD) at spe- 
cific stages of development: limb buds from Hamilton and 
Hamburger stage 24 (day 4) embryos [10], foot tendons, 
breast muscle, and liver from 19-day-old embryos, and 
vertebral cartilage and dermis from 12-day-old embryos. 
Chick articular cartilage was isolated from the tibias of 6- 
to 8-week-old ex ovo juvenile chicks. 
Primary cultures of chick vertebral chondrocytes in 
suspension and chick dermal fibroblasts were prepared and 
grown as described previously [11]. Mesenchymal cells 
were isolated from stage 24 limb buds as described [12], 
plated at low cell density (2 X 106 cells/plate) on 60-mm 
tissue culture dishes (Falcon), and allowed to grow until 
nearly confluent monolayers were formed. 
Total cellular RNA was isolated from foot tendons, 
breast muscle, and liver using density gradient centrifuga- 
tion in cesium chloride as described previously [8]. Total 
cellular RNA was isolated from embryonic vertebral carti- 
lage and juvenile articular cartilage by density gradient 
centrifugation i cesium trifluoroacetate as described [13]. 
Total cellular RNA was isolated from chick dermal fibro- 
blasts and vertebral chondrocytes by the acid phenol guani- 
dine procedure as described [14]. Poly(A)+ RNA was 
isolated from stage 24 limb buds and mesenchymal cells in 
monolayer culture using a QuickPrep kit (Pharmacia). 
2.2. Generation of a specific fibronectin cDNA by RT / PCR 
A chick fibronectin eDNA fragment containing the last 
24 nucleotides of exon IIIB and the two exons encoding 
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the type III-8 repeat was generated by RT/PCR using 
poly(A) + RNA isolated from chick stage 24 limb mes- 
enchyme tissue as a template. The primer extension reac- 
tion proceeded exactly as described previously [15] using 
VB111 (see Table 1) as the 3' oligonucleotide primer. The 
resulting cDNA was then subjected to 35 cycles (1 min, 
94°C; 2 min, 55°C; 3 min, 72°C) of amplification using a 
GeneAmp kit (Perkin-Elmer Cetus) in the presence of 25 
pmol each of VB108 and VB l l l  (see Table 1), the 5' and 
3' oligonucleotide primers, respectively. The resulting PCR 
product was electroeluted from a 2% agarose gel stained 
with ethidium bromide, digested with EcoR1 and BamH1, 
and ligated into the same sites of pGEM2 (Promega). The 
resulting plasmid, pchlimb7-9, contains 31 bases of the 3' 
end of the type III-7 repeat, all of exon IIIB, the entire 
type III-8 and III-9 repeats, and 24 bases of the 5' end of 
the type III-10 repeat. 
2.3. Sequencing 
The pchlimb7-9 eDNA fragment was sequenced by the 
dideoxynucleotide chain termination method [16] using the 
TaqTract kit from Promega and oligonucleotide primers 
corresponding to the SP6 and T7 RNA polymerase pro- 
moter regions (Promega). New oligonucleotide primers 
were synthesized as needed to complete sequencing in 
both directions across the inserts. The resulting sequence 
has been entered into GenBank as accession number 
U20386. In addition, this sequence has been combined 
with the previously reported chick cDNA sequence [6] to 
provide a continuous equence and entered into GenBank 
as accession umber U21327. 
2.4. Preparation of RNase protection assay probe 
The pchlimb7-9 plasmid (200 ng) was subjected to 35 
cycles (1 min, 94°C; 2 min, 55°C; 3 min, 72°C) of 
amplification using a GeneAmp kit (Perkin-Elmer Cetus) 
in the presence of 25 pmol of VB161 (5' primer) and 
VBll3 (3' primer) (see Table 1). The resulting PCR 
product was electroeluted from a 2% agarose gel and 
subcloned into pGEM2 as described above. The resulting 
plasmid, pchRPIII-9, contains 433 bases of chick fi- 
bronectin eDNA including 250 bases encoding most of the 
type III-8 repeat and 183 bases encoding approximately 
the 5' two-thirds of the type III-9 repeat. 
2.5. RNase protection assays 
RNase protection assays were performed exactly as 
described previously [8] using uniformly labeled tran- 
scripts resulting from the T7 RNA polymerase (Promega) 
directed in vitro transcription of EcoRI-linearized 
pchRPIII-9 plasmid as described [17]. 
2.6. RT / PCR assays for presence of type 111-9 
RT/PCR reactions were performed as described above 
using VB112 (5' primer) and VBl l l  (3' primer) (see 
Table 1) with total cellular RNA or poly(A) + RNA from 
the indicated tissues or cells as templates. Control reac- 
tions for the reverse transcription reaction for each tem- 
plate RNA were performed by eliminating only the reverse 
transcriptase from each RT reaction. Control reactions for 
the polymerase chain reaction were performed in the ab- 
sence of added template RNA (no RNA). The resulting 
PCR products were visualized on a 2% agarose gel stained 
with ethidium bromide and photographed. 
3. Results 
3.1. Determination of chick eDNA sequence corresponding 
to the 3' end of exon IIIB and the exons encoding the type 
111-8 repeat 
In order to fully characterize the fibronectin mRNA in 
cartilage with respect o all potential splice variations, we 
Cell Heparin 
Attachment Binding 
I | I 
6 7 8 9 10 11 12 13 14 k~i~:~:.~:~ ~ 1 5 
Probe 
Protected j" + I I I -  9 433 bp 
Fragments  ~L - 111-9 ~ 250 bp 
Fig. 1. Organization of the type III repeats in fibronectin. The schematic diagram represents he arrangement of type III repeats (numbered or lettered 
boxes) for a portion of chick tibronectin. The dark shaded box designated as V does not represent a type III repeat but instead serves as a type III 
connecting segment in the protein that is encoded by exon V (for variable region) in the fibronectin gene and is known to be alternatively spliced in the 
fibronectin mRNA. All other bexes represent type III repeats in the protein that are each encoded by two exons in the gene, except for type III repeats B, 
A, and 9 which are each encoded by a single exon in the fibronectin gene. The dark shaded boxes designated as B and A represent type llI repeats that are 
encoded by exons known to be alternatively spliced in the fibronectin mRNA. The box designated as 10 represents he type III-10 repeat containing the 
RGDS sequence which mediates cell adhesion to the integrin fibronectin receptor and is therefore also designated as the cell attachment domain. The 
composition of the chick-specific eDNA used as a probe in the nuclease protection assays is shown below the schematic diagram. The relative expected 
sizes of the mRNA fragments that should be protected by the probe in nuclease protection assays are also shown. 
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designed an RT/PCR method to determine if the exon 
encoding the type 111-9 repeat is present in cartilage fi- 
bronectin. The diagram in Fig. 1 shows the order of the 
type III repeats in the fibronectin molecule. The chick 
fibronectin cDNA sequence for the type 111-8 and type 
111-9 repeats, as well as the last 24 bases of exon IIIB, was 
unknown [6]; the type 111-9 genomic sequence, however, 
had been determined [18]. This gap in the cDNA sequence 
initially prohibited construction of a specific oligonucleo- 
tide 5' primer from the type 111-8 repeat for use in PCR in 
conjunction with a 3' primer from the type III-10 repeat. In 
order to determine the cDNA sequence for this gap, we 
utilized chick limb mesenchyme RNA as a template in an 
RT/PCR reaction with a 5' primer from the type 111-7 
repeat (VB108) and a 3' primer from the type I11-10 repeat 
(VB 111). Our previous work indicates that the fibronectin 
mRNA from the limb mesenchyme of stage 24 chick 
embryos contains the alternatively spliced exon IIIB [8] 
and thus should be a suitable template for determination f 
this cDNA sequence. The resulting 860 base RT/PCR 
*xon I I IB / type  I I I -8  
P T T L T Q Q T /A  V P P P T D L R F T N 
1 CCTACCACTCTGACACAGCAAACGGCCGTGCCTCCTCCCACTGATCTCCGCTTCACTAAT ch ick  
. . . . .  T - -A  . . . . . . . .  A . . . . . . . .  T - -T  . . . . . . . . . . . . . .  C - -G- -A  . . . . .  C - -C  human 
V G P D T M R V T W T A P T S I V L S S 
61  GTGGGGCCTGATACCATGAGAGTGACATGGACTGCACCGACTTCCATCGTGCTGAGCAGT ch ick  
A -T - -T - -A - -C  . . . . . .  C -T - -C - -C - - -G- -C  . . . .  CC-A  . . . . .  T -ATT-A-C- -AC human 
I * * * * * * * * * A P * P * * D * T N 
F L V R Y S P V K N E E D V A E L T I S 
121  TTCTTGGTGCGCTACTCACCTGTGAAGAAGGAGGAGGACGTTGCAGAGCTGACAATTTCA ch ick  
- - -C  . . . . . . .  T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  T - -T  . . . . . . .  T human 
P S D N V V V L T N L L P G T E Y L V R 
181 CCCTCAGACAACGTGGTGGTCTTAACAAATCTGCTCCCTGGTACTGAATATCTGGTGAGA ch ick  
- -T  . . . . . . . .  T -CA . . . . . . . . . . . . . . . . .  C - -G  . . . . . . . .  A . . . . . .  G -A  . . . . .  T human 
t~e  I i i -8  / type  i i i -9  
V Y S V A E Q H E S A P L S G I Q K T /G  
241  GTCTACAGTGTTGCTGAGCAACATGAGAGTGCGCCTTTGTCTGGAATCCAGAAAACAGGG ch ick  
. . . .  C . . . . . .  CTAC- -A  . . . . . . . . . . .  CA-A- - -C -TAGA . . . .  GA . . . . . . . . . . .  T human 
* S * * Y * * * * * T * * R * R * * * / *  
L D S P T G L D F S D I T A N S F T V H 
301  CTCGATTCCCCAACTGGCCTTGACTTCTCGGATATAACTGCTAACTCCTTCACTGTCCAC ch ick  
- -T  . . . . . . . . . . . . . . .  A . . . . . . .  T - -T  . . . . .  T . . . . .  C . . . . .  T - -T  . . . . .  G - - -  human 
W I A P R A T I T G Y K I R H H P E H G 
361 TGGATTGC TC C TCGTGC CAC CATTACGGGC TATAAGATTCGGCATC ACCC GGAGCACGGT ch ick  
. . . . . . . . . . . . . .  A . . . . . . . .  C - -T  . . . . .  C -G- - -C - -C  . . . . .  T - -C  . . . . . .  TTC human 
V G R P L E D R V P P S R N S I T L T N 
421  GTTGGCAGGCC CAAGGAGGACCGTGTGC CCCCC TCAC GAAAC TC CATCAC TCTCACCAAC ch ick  
AG-  - -G -  -A - -TCGA-  -A -  -T -  -G  . . . . . . .  A -  - -T -  -G -  -T  . . . . . . . .  C . . . . . . . . .  human 
L L P G T E Y V V S I I A V N G R E E S 
481 C TGC TCC CAGGAAC TGAGTATGTGGTCAGCATCATC GCC GTCAAC GGCAGGGAGGAGAGC ch ick  
- -CACT . . . . .  C - -A  . . . . . . . . . . . . . . . . . .  G -T - -TC-T - -T  . . . . .  A . . . . .  A - -T  human 
* T * * * * * * * * * V * L * * * * * * 
t~e  i i z -9  
V P L V G Q Q T T / 
541  GTGC C CTTGGTTGGCCAGCAGACAACC ch ick  
CCCTTA-  - -A  . . . . . . .  A -  -AT  . . . .  A human 
P L * I * * * S * / 
Fig. 2. eDNA and deduced amino acid sequences for the 3' end of exon roB, and the exons encoding the type 11I-8 and type 111-9 repeats of the chick 
fibronectin gene. Comparison of the chick amino acid (deduced) and cDNA sequences (upper two lines) for the 3' end of exon I1/B and the two exons 
encoding the type I/1-8 repeat o the published human sequences [2] (bottom two lines) corresponding to the same region. The deduced amino acid and 
eDNA sequences for the exon encoding the type ffl-9 repeat, identical to the previously reported chick genomic sequence for this exon [18], is also shown. 
Numbers to the left of each line of sequence represent the base numbers corresponding to the first base of each line. -, nucleotide identity; *, amino acid 
identity. 
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product was cloned into pGEM2 and the resulting clone, 
pchlimb7-9, was sequenced by the dideoxynucleotide chain 
termination method [16] a,; described in Section 2. Fig. 2 
shows the chick fibronectin cDNA sequence corresponding 
to the last eight amino acids of exon IIIB, the two exons 
encoding the type 111-8 repeat, and the exon encoding the 
type 11I-9 repeat. This cDNA sequence was confirmed with 
sequence generated from additional RT/PCR reactions 
using cartilage (contains exon IIIB) and liver (does not 
contain exon IIIB) RNA as templates. Even though liver 
fibronectin RNA does not contain the alternatively spliced 
exon IIIB, it does contain all of the exons encoding the 
type 111-8 and type 111-9 repeats. The chick cDNA and 
deduced amino acid sequences for this region are similar 
to the human sequences [2] as indicated in Fig. 2. Further- 
more, the chick cDNA sequence for the type 111-9 repeat is 
identical to the chick genomic sequence corresponding to 
this exon [18]. 
3.2. Analysis of the presence of the exon encoding the type 
111-9 repeat in fibronectin mRNA from cartilage and other 
mesenchymal tissues by RNase protection assay and RT /  
PCR 
Utilizing the pchlimb7-9 plasmid as a template for a 
PCR reaction with additional 5' and 3' oligonucleotide 
primers (VB161 and VBII13, respectively; see Table 1), 
we prepared and subcloned a 433 base fibronectin cDNA 
fragment, pchRPIII-9, containing 250 bases of the 3' end 
of the type 111-8 repeat and 183 bases of the 5' end of the 
type 111-9 repeat into pGEIvl 2 as described in Section 2. In 
vitro transcription of the EcoRI-linearized pchRPIII-9 with 
T7 RNA polymerase in the presence of a-[ 32 P]ATP gener- 
ated uniformly-labeled transcripts for use as an RNase 
protection assay probe. "[he results of RNase protection 
assays using this probe with RNA isolated from liver (lane 
4), tendon (lane 5), breast muscle (lane 6), stage 24 limb 
mesenchyme (lane 7), vertebral chondrocytes (lane 8), and 
vertebral cartilage (lane 9) are shown in Fig. 3. A large 
protected fragment (433 bases) corresponds to fibronectin 
mRNA containing the exon encoding the type III-9 repeat, 
whereas a short protected fragment (250 bases) would 
correspond to fibronectin mRNA with the exon missing 
(Fig. 1). The assays indicate that all of the fibronectin 
mRNA in all of these tissues, including cartilage, contains 
the exon encoding the type III-9 repeat. 
Because of the need to test other tissues where less 
RNA is often available, we performed RT/PCR reactions 
using oligonucleotide primers from the 3' end of the type 
III-8 repeat (VBl l2)  and the 5' end of the type III-10 
repeat (VB111) (see Table 1) with the RNA isolated from 
several different cells and tissues of mesenchymal origin 
as the templates. The results of this assay are shown in 
Fig. 4. The major RT/PCR product in each case is 475 
bases which corresponds to the expected RT/PCR product 
size if the exon encoding the type III-9 repeat is present in 
517 
460 - 
396 
350  - 
222  
tt~ 
0 
0,9 
433 
250  
1 2 3 4 5 6 7 8 9 
Fig. 3. RNase protection assays for determination of the presence ofthe 
exon in the fibronectin mRNA encoding the type 111-9 repeat. RNase 
protection assays were performed asdescribed in Section 2by hybridiza- 
tion of uniformly labeled T7 transcripts from the EcoRI-linearized 
pchRPllI-9 plasmid to total cellular or poly(A)+ RNA isolated from the 
indicated tissues or cells. Unhybridized RNA was then digested with 
RNases A and T1, and the resulting protected fragments were subjected 
to electrophoresis through an 8% polyacrylamide g lcontaining 8 M 
urea. No RNA (lane 3) represents anRNase protection assay containing 
only nuclease-free transfer RNA (BioRad) as the sample RNA. Markers 
represent end-labeled fragments of pGEM3 digested with Hinfl, RsaI, 
and SinI (Promega Biotec) with the indicated sizes. A large protected 
fragment (433 bases) corresponds to fibronectin mRNA containing the 
exon encoding the type I11-9 repeat, while a short protected fragment (250 
bases) would correspond to fibronectin mRNA where the exon is missing. 
the fibronectin mRNA. No band appears for any of these 
cells or tissues that corresponds to the expected RT/PCR 
product size of 205 bases if the exon encoding the type 
III-9 repeat is absent from the fibronectin mRNA. Thus all 
of the fibronectin mRNA in these cells and tissues, includ- 
ing cartilage, contain the exon encoding the type III-9 
repeat. One minor band corresponding to a fragment of 
approximately 150 bases appears in the reactions contain- 
ing reverse transcriptase (odd numbered lanes) for several 
of the samples, that does not appear in the reactions 
completed in the absence of reverse transcriptase. This 
band is significantly smaller than the expected 205 base 
fragment that would appear if the exon encoding the type 
III-9 repeat was spliced out of the fibronectin mRNA 
isolated from the various cells and tissues. Thus this minor 
band most likely represents an artifactual amplification of 
a non-fibronectin mRNA species. 
The RT/PCR results confirm those obtained by the 
RNase protection assays for liver, tendon, limb mes- 
enchyme, vertebral chondrocytes in suspension culture, 
and vertebral cartilage. In addition, the RT/PCR assays 
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Fig. 4. RT/PCR assays for the determination f the presence of the exon in the fibronectin mRNA encoding the type III-9 repeat. RT/PCR assays were 
performed as described in Section 2 with oligonucleotide primers from the type III-8 (VB 112) and the type III-10 repeat (VB 111) of the chick fibronectin 
gene. The upper panel is an ethidium bromide stained agarose gel containing RT/PCR products resulting from the use of total cellular or poly(A) + RNA 
isolated from the indicated cells or tissues in the presence (odd-numbered lanes) or absence (even-numbered lanes) of reverse transcriptase. Markers (lane 
19) are fragments of pGEM3 digested with Hinfl, RsaI, and SinI (Promega Biotec). The lower panel represents a schematic diagram of the possible 
splicing patterns of the exon encoding the type IH-9 repeat for chick fibronectin mRNAs, and the expected size of the corresponding PCR product. 
indicate that the exon encoding the type III-9 repeat is also 
present in the fibronectin mRNA isolated from skin fibro- 
blasts, mesenchymal cells in monolayer culture, and juve- 
nile articular cartilage. Thus, the type III-9 repeat, although 
encoded by a single exon, appears to be constitutively 
present in the fibronectin mRNA from all chick cells and 
tissues of mesenchymal origin, including cartilage. 
4. Discussion 
Chondrogenesis, the differentiation f mesenchyme into 
cartilage, is characterized by a dramatic change in the 
composition of the extracellular matrix. Mesenchymal cells, 
prior to overt chondrogenesis, produce a matrix containing 
primarily type I collagen, various heparan sulfate proteo- 
glycans, and fibronectin. In contrast, cartilage is composed 
of a unique matrix containing large amounts of types II, 
IX, and XI collagens and aggrecan, the large aggregating 
chondroitin sulfate-containing proteoglycan (reviewed in 
Refs. [19,20]). Fibronectin is also present in the cartilage 
matrix [21-23], but we have shown previously that the 
structure of the fibronectin mRNA in chick embryonic 
cartilage differs from the mRNA present in limb mes- 
enchyme and other cells and tissues of mesenchymal ori- 
gin [8]. This structural heterogeneity results from the alter- 
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native splicing of exons IIIB, IliA, and V during RNA 
process ing events in a t issue-specif ic  and 
developmentally-regulated manner in these tissues. Specif- 
ically, all of the fibronectin mRNA from cartilage contains 
exon IIIB and exon V but does not contain exon IliA 
(B + A - V + ), whereas all of the fibronectin mRNA in 
limb mesenchyme prior to .avert chondrogenesis contains 
exon IliA, exon IIIB, and exon V (B + A + V + ) [8]. 
The localization of a cell adhesion synergy site within 
the type 11I-9 repeat [24-26] suggests a potentially impor- 
tant functional significance for this particular type III 
repeat. Determination of whether or not the exon encoding 
the type 111-9 repeat is pre,;ent in the fibronectin mRNA 
from cartilage and other cells and tissues of mesenchymal 
origin was therefore crucial for complete characterization 
of the structure, and eventually the function, of fibronectin 
in cartilage and during chondrogenesis. However, the chick 
cDNA sequence corresponding to the 3' end of exon IIIB 
and the two exons encodiag the type 11I-8 repeat was 
unknown when we initiated these experiments, making the 
design of oligonucleotide primers for RT/PCR assays 
difficult. The completed cD.NA sequence reveals that the 
deduced amino acid sequence for the last 24 nucleotides of 
exon IIIB of the chick fibronectin gene is identical to the 
corresponding sequence of human fibronectin (see Fig. 2) 
resulting in 97% identity for the entire exon IIIB. In 
addition, the chick and huraan amino acid sequences for 
the type 111-8 repeat are 82% identical (see Fig. 2) similar 
to the overall average identity of 81% for the entire 
chicken and rat fibronectin proteins. Furthermore, the chick 
cDNA and deduced amino acid sequences for the exon 
encoding the type 11I-9 repeat is 100% identical to the 
corresponding region of the previously determined chick 
genomic sequence [18]. qTae complete cDNA sequence 
corresponding to this entire region of the chick fibronectin 
gene now provides the information ecessary for DNA 
manipulations involving this region. For example, we have 
utilized the cDNA sequence for the last 24 bases of exon 
IIIB to subclone the entire chick exon IIIB cDNA into an 
Escherichia coli expression vector system for overexpres- 
sion of the peptide ncoded by the chick exon IIIB (White, 
Hall, Brandli, Gehris, and Bennett; manuscript submitted). 
As indicated earlier in this communication, we also uti- 
lized the sequence information to prepare an RNase protec- 
tion probe, pchRPIII-9, and for designing oligonucleotide 
primers for use in RT/PCR assays for determining whether 
the type 111-9 repeat is present in the fibronectin mRNA 
from chick cartilage tissues and other cells and tissues of 
mesenchymal origin. 
The results of both RNase protection (Fig. 3) and 
RT/PCR assays (Fig. 4) indicate that all of the fibronectin 
mRNA in chick embryonic vertebral and adult articular 
cartilage as well as limb mesenchyme tissues contains the 
exon encoding the type 11I-9 repeat. In addition, all of the 
fibronectin mRNA from other cells and tissues of mes- 
enchymal origin (skin fibroblasts, tendon and skeletal mus- 
cle) contains this exon. Thus the exon encoding the type 
11I-9 repeat appears to be constitutively present in the 
fibronectin mRNA in all cells and tissues of mesenchymal 
origin, including cartilage. Furthermore, the splicing pat- 
tern of the type 111-9 repeat does not appear to change 
when cells from these tissues are grown in culture (vertebral 
chondrocytes in suspension culture, mesenchymal cells in 
monolayer culture, and skin fibroblasts). This result indi- 
cates that the culture systems for these cells do not alter 
the splicing pattern of the exon encoding the type 111-9 
repeat. 
The observation that the exon encoding the type 111-9 
repeat does not appear to be alternatively spliced in these 
mesenchymal tissues or other cells examined to date ([4,9], 
P. Norton, personal communication) is somewhat surpris- 
ing since neither the 3' or 5' splice sites for this exon 
appear particularly strong. Fig. 5 shows a comparison of 
the splice sites for the exon encoding the type 11I-9 repeat 
Consensus  
Type / I I -10A 
(ch ick}  
Exon I I IA 
( human ) 
Exon IZIB 
(chLok)  
Type I I I -9 
(ch ick )  
3' Spl ice Site 5' Spl ice Site 
5 ' . . .YYYYYYYYYYNCAG/R  . . . . . . . . . .  NAG/GTRAGT . . . .  3 '  
5 ' . . .TTCTGTTTTCCTAG/T  . . . . . . . . . .  CAG/GTGAGG . . . .  3 '  
5 ' . . .AATTTGCCTAACAG/A  . . . . . . . . . .  CAG/GTATAT . . . .  3 '  
****  ***  * **  * * * 
S ' . . .CTTTAACTCATTAG/G . . . . . . . . . .  ACG/unknown. . .3 '  
5 ' . . .TTCGAAACACCTAG/G . . . . . . . . . .  CCG/GTAAGC . . . .  3 '  
Fig. 5. Comparison of the 3' and 5' splice sites for the exon encoding the chick type 111-9 repeat with other constitutive and alternatively spliced exons. The 
consensus sequences for the 3' and 5' splice sites (top line) are compared to a constitutively included exon (type III-10A; second line), the alternatively 
spliced exons I/IA (third line) and IIIB (fourth line), and to the exon encoding the type 111-9 repeat (bottom line). N, any nucleotide; Y, pyrimidine 
nucleotides C and T; R, purine nucleotides A and G; star ( * ) located above a nucleotide, nucleotide matches the consensus sequence. 
12 A.L. Gehris et al. / Biochimica et Biophysica Acta 1311 (1996) 5-12 
(sequence derived from Ref. [18]) with the constitutively 
included exon encoding the first portion of the type III-10 
repeat [18], the alternatively spliced exons IliA [27] and 
IIIB [28], and the splice site consensus sequences [27]. The 
comparison reveals that the 3' splice site, in particular, is 
purine-rich and thus seems relatively weak for a constitu- 
tively included exon. The 5' splice site appears imilar to 
the 5' splice site for the alternatively spliced exon IIIB [28] 
but somewhat stronger than the 5' splice site for the 
alternatively spliced exon IIIA [27]. The constitutive inclu- 
sion of the exon encoding the type 111-9 repeat in the 
fibronectin mRNA from several cells and tissues ([4,9], 
this communication), even though the type 111-9 repeat is 
encoded by a single exon with moderately weak splice 
junctions, suggests that these structural features do not 
adequately predict whether an exon is alternatively spliced 
or not. Thus the exon encoding the type 111-9 repeat will 
serve as a useful control exon for examining the regulation 
of tissue-specific alternative splicing. In fact, chimeras 
between the exon encoding the type 111-9 repeat and exon 
IIIB have been utilized to identify cis-acting elements 
responsible for the regulation of exon IIIB alternative 
splicing [29]. We plan to utilize the exon encoding the type 
111-9 repeat in a similar manner for examining the tissue- 
specific and developmental regulation of exon IliA alterna- 
tive splicing during chondrogenesis since this exon is not 
alternatively spliced in chick limb mesenchyme or carti- 
lage tissues. 
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